1. Scrip
  2. >>Advanced Therapies
  3. >>Cell Therapies

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

(Alaric DeArment)

Gilead Sciences division Kite is aiming for its bicistronic anti-CD19/CD20 CAR-T therapy KITE-363 to be able to both tamp down toxicity in patients with B-cell lymphomas and to prevent CD19-negative relapses, a persistent problem with CAR-T cell therapies that target CD19 such as Gilead’s Yescarta (axicabtagene ciloleucel).

Key Takeaways
  • KITE-363 is designed to be able to overcome CD19 antigen-negative relapse and also lower toxicity and improve persistence thanks to its bicistronic design incorporating dual antigen targeting and dual costimulatory domains.

On May 30 at the American Society of Clinical Oncology (ASCO) meeting in Chicago, the drugmaker presented data from its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell Therapies

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By Xu Hu

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

More from R&D

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 
• By Alaric DeArment

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.